Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.17 -1.3%	$1.35	$0.86 ▼ $3.78	$254.82M	0.6	3.31 million shs	3.02 million shs
ANNX Annexon	$2.09 -4.1%	$1.81	$1.29 ▼ $7.85	$229.30M	1.24	1.79 million shs	3.87 million shs
AQST Aquestive Therapeutics	$2.70 -3.2%	$2.66	$2.12 ▼ $5.80	$268.19M	2.02	1.50 million shs	753,836 shs
SKYE Skye Bioscience	$1.98 -6.6%	$1.99	$1.14 ▼ $12.11	$61.33M	1.74	367,587 shs	231,900 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+9.91%	-31.47%	-35.28%	-53.40%
ANNX Annexon	0.00%	-0.95%	+6.09%	-12.55%	-56.73%
AQST Aquestive Therapeutics	0.00%	+14.89%	-10.00%	+1.89%	-6.25%
SKYE Skye Bioscience	0.00%	+5.16%	-11.12%	-20.40%	-82.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.769 of 5 stars	4.5	3.0	2.8	3.3	0.6
ANNX Annexon	2.0641 of 5 stars	3.5	1.0	3.6	0.8	0.6
AQST Aquestive Therapeutics	1.3398 of 5 stars	3.5	1.0	2.9	0.0	0.0
SKYE Skye Bioscience	1.2442 of 5 stars	3.5	2.0	1.4	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	624.85% Upside
ANNX Annexon	3.00	Buy	$12.50	498.09% Upside
AQST Aquestive Therapeutics	3.00	Buy	$10.67	295.06% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	738.38% Upside

Current Analyst Ratings Breakdown

Latest SKYE, AQST, ALLO, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/14/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $14.00
5/13/2025	ANNX Annexon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $11.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	11,582.80	N/A	N/A	$3.04 per share	0.38
ANNX Annexon	N/A	N/A	N/A	N/A	$3.20 per share	N/A
AQST Aquestive Therapeutics	$54.23M	4.95	N/A	N/A	($1.59) per share	-1.70
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	($0.17) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.23	N/A	N/A	N/A	N/A	-52.13%	-41.29%	8/6/2025 (Estimated)
ANNX Annexon	-$134.24M	-$1.18	N/A	N/A	N/A	N/A	-38.99%	-33.90%	8/11/2025 (Estimated)
AQST Aquestive Therapeutics	-$7.87M	-$0.59	N/A	N/A	N/A	-59.75%	N/A	-33.96%	8/5/2025 (Estimated)
SKYE Skye Bioscience	-$37.65M	-$0.82	N/A	N/A	N/A	N/A	-45.78%	-37.44%	N/A

Latest SKYE, AQST, ALLO, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/12/2025	Q1 2025	ANNX Annexon	-$0.30	-$0.37	-$0.07	-$0.37	N/A	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
3/20/2025	Q4 2024	SKYE Skye Bioscience	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A
3/13/2025	Q4 2024	ALLO Allogene Therapeutics	-$0.34	-$0.28	+$0.06	-$0.28	$0.01 million	N/A
3/5/2025	Q4 2024	AQST Aquestive Therapeutics	-$0.14	-$0.19	-$0.05	-$0.19	$13.11 million	$11.87 million
3/3/2025	Q4 2024	ANNX Annexon	-$0.28	-$0.33	-$0.05	-$0.33	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
ANNX Annexon	N/A	17.17	17.18
AQST Aquestive Therapeutics	N/A	6.37	5.91
SKYE Skye Bioscience	N/A	14.19	14.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
ANNX Annexon	N/A
AQST Aquestive Therapeutics	32.45%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
ANNX Annexon	11.87%
AQST Aquestive Therapeutics	8.35%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	158.72 million	Optionable
ANNX Annexon	60	109.71 million	93.09 million	Optionable
AQST Aquestive Therapeutics	160	99.33 million	84.02 million	Optionable
SKYE Skye Bioscience	11	30.98 million	29.43 million	Optionable

SKYE, AQST, ALLO, and ANNX Headlines

Recent News About These Companies

Skye Bioscience (NASDAQ:SKYE) Trading Up 24% - Here's What Happened

May 31 at 2:48 AM | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Trading Up 24% - Should You Buy?

May 30 at 2:51 AM | americanbankingnews.com

Leo Miller: Page 6

May 25, 2025 | entrepreneur.com

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

May 23, 2025 | zacks.com

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025 | globenewswire.com

Skye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity Treatment

May 21, 2025 | nasdaq.com

Q&A: Next wave of obesity drugs may ‘afford a lot of advantages’

May 20, 2025 | healio.com

Arecor shares climb 18% on collaboration with Skye Bioscience

May 19, 2025 | lse.co.uk

Arecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate Nimacimab

May 19, 2025 | cambridgenetwork.co.uk

Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025 | finanznachrichten.de

Arecor enters formulation partnership with Skye Bioscience

May 19, 2025 | sharecast.com

Arecor shares jump 10% on obesity drug partnership with Skye Bioscience

May 19, 2025 | proactiveinvestors.co.uk

Arecor partners with Skye Bioscience to improve formulation of obesity drug

May 19, 2025 | proactiveinvestors.co.uk

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025 | globenewswire.com

Ensign Peak Advisors Inc Sells 132,713 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE)

May 18, 2025 | marketbeat.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of "Buy" from Analysts

May 16, 2025 | marketbeat.com

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025 | globenewswire.com

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025 | globenewswire.com

Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...

May 12, 2025 | medpagetoday.com

Skye Bioscience (NASDAQ:SKYE) Issues Quarterly Earnings Results

May 12, 2025 | marketbeat.com

Earnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D Expansion

May 10, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
By Leo Miller | May 6, 2025
View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

SKYE, AQST, ALLO, and ANNX Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.16 -0.02 (-1.27%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.17 +0.00 (+0.43%)

As of 03:59 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Annexon NASDAQ:ANNX

$2.09 -0.09 (-4.13%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.04 -0.05 (-2.39%)

As of 03:59 AM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Aquestive Therapeutics NASDAQ:AQST

$2.70 -0.09 (-3.23%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.71 +0.01 (+0.37%)

As of 03:59 AM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Skye Bioscience NASDAQ:SKYE

$1.98 -0.14 (-6.60%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.98 0.00 (0.00%)

As of 03:59 AM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time